Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease - Trial NCT06047002

Timeline & Enrollment

Primary Outcome

To examine the feasibility of using the VerifyNow PRU and Aspirin assays to obtain estimates of the prevalence of resistance to antiplatelet therapy (aspirin & clopidogrel) in patients with symptomatic peripheral arterial disease.

Summary

Peripheral arterial disease (PAD) is a condition where the blood vessels in the legs get
 blocked. It affects one out of every five adults over the age of 65. As it is the main cause
 of amputations, the NHS performs over 20,000 operations every year to prevent them. People
 with PAD benefit from tablets to thin their blood as this improves outcomes after surgery and
 prevents heart attacks and strokes. The main tablets for this purpose are aspirin and
 clopidogrel. These work in most people, but up to a third of patients do not get any benefit
 from them, as their bodies cannot process them. We call this resistance to therapy
 (RT).Because blood thinning is particularly important after operations people with RT may be
 at higher risk of their operation failing leading to amputation and/or problems such as heart
 attacks and strokes. Testing for RT has not traditionally been performed because it requires
 complex laboratory procedures. Recent development in technology now means that bedside tests
 are available for RT. We will use a simple beside test for RT in patients with severe PAD. We
 will use this test to see how many of these patients have RT and whether this affects their
 risk of complications after an operation. If we find that RT does affect outcomes for
 patients with PAD, the information obtained will be used to plan future research to determine
 if changing blood thinning therapy in people with CR improves their outcomes after surgery.

ICD-10 Classifications